Skip to NavigationSkip to content

Pharmafile - Medical Communications News

In the last week, a number of COVID-19 vaccine developments have been made. Johnson & Johnson’s one-shot jab was found to be 85% effective,...
Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 that have arisen in the...
Pfizer has withdrawn its application in India for emergency use authorisation of its vaccine, which it has produced with German biotechnology...
Hyloris Pharmaceuticals and Purna Female Healthcare, a spin-off founded by Purna Pharmaceuticals and Creafund, have entered into a partnership to...
AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer in...
Most of Pharmafile.com’s top stories this week concern the approval of various treatments in the US, UK, and EU – but Bristol Myers Squibb has seen...
Germany’s main public health body has recommended that AstraZeneca’s COVID-19 vaccine is only administered to those aged between 18 and 64 years.
Novavax has announced that its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated an efficacy of 89.3% in its UK Phase III trial.
Toxys, Leiden University, and Leiden University Medical Center have agreed to commercialise and develop further the ToxProfiler technology invented...
RedHill Biopharma has announced a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib (Yeliva...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches